1. Home
  2. GERN vs LPTH Comparison

GERN vs LPTH Comparison

Compare GERN & LPTH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Geron Corporation

GERN

Geron Corporation

HOLD

Current Price

$1.10

Market Cap

1.0B

Sector

Health Care

ML Signal

HOLD

Logo LightPath Technologies Inc.

LPTH

LightPath Technologies Inc.

BUY

Current Price

$7.30

Market Cap

1.1B

Sector

Technology

ML Signal

BUY

Company Overview

Basic Information
Metric
GERN
LPTH
Founded
1990
1985
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Semiconductors
Sector
Health Care
Technology
Exchange
Nasdaq
Nasdaq
Market Cap
1.0B
1.1B
IPO Year
1996
2011

Fundamental Metrics

Financial Performance
Metric
GERN
LPTH
Price
$1.10
$7.30
Analyst Decision
Buy
Strong Buy
Analyst Count
5
5
Target Price
$4.25
★ $15.80
AVG Volume (30 Days)
★ 5.9M
2.5M
Earning Date
11-04-2026
11-10-2026
Dividend Yield
N/A
N/A
EPS Growth
★ 51.85
N/A
EPS
★ N/A
N/A
Revenue
$1,065,000.00
★ $37,202,630.00
Revenue This Year
$28.49
$49.41
Revenue Next Year
$44.73
$41.87
P/E Ratio
★ N/A
N/A
Revenue Growth
N/A
★ 17.26
52 Week Low
$1.04
$5.83
52 Week High
$2.01
$18.94

Technical Indicators

Market Signals
Indicator
GERN
LPTH
Relative Strength Index (RSI) 32.01 30.79
Support Level $1.08 N/A
Resistance Level $1.26 $10.67
Average True Range (ATR) 0.05 0.57
MACD -0.00 -0.18
Stochastic Oscillator 8.33 10.78

Price Performance

Historical Comparison
GERN
LPTH

About GERN Geron Corporation

Geron Corp is a biopharmaceutical company focused on blood cancers. Its telomerase inhibitor, RYTELO (imetelstat), is approved in the United States and European Union for certain adult patients with lower-risk myelodysplastic syndromes (LR-MDS) with transfusion-dependent anemia. RYTELO inhibits telomerase activity in malignant stem and progenitor cells, which may reduce abnormal cell proliferation while supporting the production of healthy cells. It is also conducting a Phase 3 trial of imetelstat in patients with JAK-inhibitor-refractory or relapsed myelofibrosis (R/R MF) and studies in other hematologic malignancies. The company operates as a single segment, being the development of therapeutic products for oncology.

About LPTH LightPath Technologies Inc.

LightPath Technologies Inc manufactures, distributes, and integrates proprietary optical components and assemblies. It develops optical solutions for traditional optics and communications markets. The company's products include precision molded optics and infrared products, serving markets such as distribution, laser, industrial, instrumentation, telecommunications, and defense. Its products are categorized as infrared components, visible components, assemblies and modules, and engineering services. G5 Infrared's revenue mainly comes from infrared components and assemblies.

Share on Social Networks: